[EN] HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE RÉCEPTEUR DE DÉCLENCHEMENT EXPRIMÉ SUR DES AGONISTES DE CELLULES MYÉLOÏDES 2 ET PROCÉDÉS D'UTILISATION
摘要:
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
The invention relates to compounds of Formula (0):
wherein A
1
-A
8
, R
4
and R
5
each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
[EN] HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME<br/>[FR] HÉTÉROARÈNES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS PROCÉDÉS D'UTILISATION
申请人:REPARE THERAPEUTICS INC
公开号:WO2023220831A1
公开(公告)日:2023-11-23
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
[EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:HOFFMANN LA ROCHE
公开号:WO2015025026A1
公开(公告)日:2015-02-26
The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
[EN] HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE RÉCEPTEUR DE DÉCLENCHEMENT EXPRIMÉ SUR DES AGONISTES DE CELLULES MYÉLOÏDES 2 ET PROCÉDÉS D'UTILISATION
申请人:[en]VIGIL NEUROSCIENCE, INC.
公开号:WO2023086800A1
公开(公告)日:2023-05-19
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).